UC Davis School of Medicine was a site for multiple COVID-19 vaccine trials

UC Davis School of Medicine tests potential COVID-19 treatments and vaccines


19 months and nearly 43 million cases after the first confirmed COVID-19 infection in the U.S., the search for safe and effective treatments continues at the UC Davis School of Medicine.

As the pandemic spread around the globe, researchers at the School of Medicine partnered with drug developers and funding agencies to find and test potential therapies and vaccines to SARS-CoV-2, the virus that causes COVID-19.

"UC Davis School of Medicine, renowned for its research expertise, is a trusted partner on many COVID-19 clinical trials and research studies. We are immensely grateful to all our researchers who continue to be at the forefront of efforts to cure this terrible disease," said Allison Brashear, the dean of the UC Davis School of Medicine.

UC Davis School of Medicine was a site for multiple COVID-19 vaccine trials

UC Davis received about $42 million in COVID-19 research funds in 2020-21. The School of Medicine’s share was more than two-thirds of that, nearly $28.5 million.

With more than 75 COVID-19 research grants, the School Medicine conducted at least 28 studies to find potent treatments and vaccines.

Ongoing clinical trials for potential COVID-19 treatments

UC Davis School of Medicine researchers are currently recruiting for multiple clinical trials, including those using stem-cell-based therapies, monoclonal antibodies, and other experimental drugs. These include:

  • Adjustment on Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients (ADIVKT): This study looks at the effect of immunosuppression reduction on antibody response to a third dose of mRNA COVID vaccine in kidney transplant patients.
  • Capricor's IV drug: This study tests how well intravenous infusions of CAP-1002 work in hospitalized patients with coronavirus. CAP-1002, based on cardiac stem cell tissues, could decrease inflammation, block or prevent tissue scarring, and stimulate new tissue growth.
  • Remdesivir and other medications (I-SPY COVID): This study seeks to determine if the antiviral drug remdesivir used alone or in combination with other drugs can treat COVID-19 and reduce the recovery time for those with severe symptoms.
  • ACTIV-3: This publicly funded study tests several agents against COVID, among them, AstraZeneca’s experimental antibody (AZD7442) and Pfizer’s antiviral drug (PF-07304814) to see if these can reduce the severity of the disease and shorten hospital stays for people with COVID-19.
  • Selinexor (KPT-330): This study is investigating whether Selinexor, an FDA-approved drug for treating multiple myeloma, speeds up the recovery of COVID-19 patients and reduces their viral load, hospital stay, and complications or chance of dying, compared to standard of care treatment.
  • Regeneron's monoclonal antibody cocktail: This study is looking at Regeneron's combined monoclonal antibodies (REGN10933 + REGN10987) as a treatment for non-hospitalized patients with COVID-19. Monoclonal antibodies are a special kind of manufactured antibodies that restore, enhance, or mimic the natural immune system. These antibodies are also being tested for household members of patients with COVID-19.
  • Isavuconazole to prevent COVID-19-associated pulmonary aspergillosis: This study is to find out more about the prevention of fungal infections, specifically aspergillosis, in people with COVID-19 infection. Researchers are testing whether the drug isavuconazole can decrease the time COVID patients stay in the ICU and the hospital.
  • Experimental stem cells for the treatment of acute respiratory distress syndrome (ARDS): This publicly-funded trial aims to see how effective mesenchymal stromal cells – a type of stem cells - are in reducing inflammation associated with ARDS and in helping damaged lungs repair themselves. ARDS is one of the severe complications of COVID-19 infection.

The researchers also recruited for multiple clinical trials, including:

COVID-19 vaccine testing

The UC Davis School of Medicine has also taken part in testing potential COVID-19 vaccines, including the now FDA-approved Pfizer vaccine for adults and the under-review Novavax vaccine for adults and children (12-17 years old).

Currently, researchers are testing a booster COVID-19 Pfizer shot to adults. They are also assessing SARS CoV-2 infection, viral shedding and potential transmission in young adults immunized with the Moderna's vaccine.

Developing rapid COVID-19 tests

UC Davis Department of Pathology and Laboratory Medicine partnered with industry to develop rapid COVID-19 test

With the advent of the pandemic, clinical lab scientists at UC Davis Department of Pathology and Laboratory Medicine developed an in-house COVID-19 test. Their remarkable achievement was a testament to a great interdisciplinary teamwork culture spanning across many departments.

One notable collaboration between UC Davis School of Medicine and the industry is the development of a rapid COVID-19 test. The new test uses an analytical instrument known as a mass spectrometer, which is paired with a powerful machine-learning platform to detect SARS-CoV-2 in nasal swabs.

Other COVID-19-related studies at UC Davis School of Medicine

Researchers are also conducting studies to better understand COVID-19 and how it impacts people and their health. Some of these studies include:

"We take this opportunity to thank all of the participants who volunteer in our clinical trials," said Timothy Albertson, chair of internal medicine at UC Davis School of Medicine and principal investigator on multiple COVID-19 clinical trials. "Their contribution helps to save lives and push science forward."

Learn more about how to sign up for UC Davis Health clinical trials or studies here.